Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Chemotherapy and Bevacizumab in RAS Mutated or Right-Sided MSS Colorectal Cancer
NCT06566755Phase 3Recruiting
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cadonilimab in colorectal cancer (CRC). Primary endpoint: Progression-free Survival at 1 year. Started Feb 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06566755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566755.